Investors
MD Medical Group Today
Investment Case
01
02
03
04
05
Revenue
Rub43.5 bn
for 2025
EBITDA
Rub13.3 bn
for 2025
Profit
up to 100%
may be allocated to dividends
Cash
Rub2,7 bn
as at 31.12.2025
Key Financials
| 2025 | 2024 | 2023 | 2022 | 2021 | |
| Revenue, Rub mln | 43,455 | 33,122 | 27,631 | 25,222 | 25,220 |
| EBITDA, Rub mln | 13,289 | 10,681 | 9,218 | 7,924 | 8,276 |
| EBITDA margin, % | 31 | 32 | 33 | 31 | 33 |
| Net profit, Rub mln | 11,035 | 10,175 | 7,823 | 4,719* | 6,143 |
| Net margin, % | 25 | 31 | 28 | 19 | 24 |
| CAPEX, Rub mln | 4,266 | 2,273 | 3,580 | 1,169 | 3,790 |
| Net debt/EBITDA | 0.03x | -0.4x | -1.0x | -0.5x | 0.2x |
*In 2022 adjusted for impairment of CIP, PPE and goodwill amounted to RUB 1,287 million. Adjusted net profit was RUB 6,005 million
Annual reports
MD Medical Group Annual Report
PDF
2025
MD Medical Group Annual Report
PDF
2024
MD Medical Group Annual Report
PDF
2023
MD Medical Group Annual Report
PDF
2022
Share capital structure
Corporate Governance
MD Medical adheres to the highest standards of corporate governance. The Company has an effective system of corporate governance and internal control of financial and economic activities that complies with Russian legislation, the rules of the Moscow Exchange, and the best international practices.
Continuous improvement of the corporate governance system is one of the main long-term strategic priorities of the Company.
More
Events Calendar
July
31
2Q 2026 Operating results
August
28
1H 2026 Financial results
